PROLOR Biotech To Present New Data On Its Long-Acting Human Growth Hormone And Long-Acting Oxyntomodulin At ENDO 2013

PROLOR Biotech To Present New Data On Its Long-Acting Human Growth Hormone And
                    Long-Acting Oxyntomodulin At ENDO 2013

-- hGH-CTP and MOD-6030 to be Featured in Oral and Poster Presentations at
Endocrine Society's Annual Meeting --

PR Newswire

SAN FRANCISCO and NES-ZIONA, Israel, June 13, 2013

SAN FRANCISCO and NES-ZIONA, Israel, June 13, 2013 /PRNewswire/ --PROLOR
Biotech, Inc. (NYSE MKT: PBTH), today announced that the company will present
new data on its long-acting human growth hormone (hGH-CTP) in Phase III
development for the treatment of growth hormone deficiency and its long acting
oxyntomodulin (MOD-6030) in preclinical development for the treatment of
obesity and type 2 diabetes at ENDO 2013, the 95^th Annual Meeting of the
Endocrine Society.

PROLOR's scientists will present additional pre-clinical and clinical safety
data on hGH-CTP and will discuss its manufacturing process. Data previously
reported by the company confirmed that hGH-CTP appears to be safe and well
tolerated and that it has the potential to be administered once-weekly to
adults with growth hormone deficiency. The new data provides further
information on the excellent safety and tolerability profile of hGH-CTP in a
variety of pre-clinical and clinical studies. PROLOR recently announced that
it has initiated a pivotal Phase III study of hGH-CTP in growth hormone
deficient adults.

In addition, PROLOR scientists will make an oral presentation discussing
MOD-6030, also known as LA-Oxyntomodulin, the company's long-acting GLP-1 and
Glucagon dual agonist with potential for the treatment of type 2 diabetes and
obesity. New pre-clinical data will be presented on MOD-6030's effects on
weight reduction and glucose tolerance in animal models.

The PROLOR presentations include the following:

FP02-3: The Long-Acting Dual GLP-1/Glucagon Agonist, Mod-6030, Improves
Glycemic Control and Induces a Prolonged Weight Loss in Diet-Induced Obesity
Mice Following a Once-Weekly Administration. See abstract for more

SAT-120: Metabolic and Safety Parameters of Once-Weekly, CTP-Modified Human
Growth Hormone (MOD-4023): Results of a Phase 2 Dose and Frequency Finding
Study. See abstract for more information.

SAT-644: Pre-clinical Characterization of MOD-4023, a Long-Acting Growth
Hormone. See abstract for more information.

SAT-647: Highly Producing Fed-Batch Manufacturing Process of Long-Acting
Human Growth Hormone (MOD-4023) in CHO Cells. See abstract for more

SUN-637: Development of a Population Pharmacokinetic and Pharmacodynamic
Model Following a Phase II Study of MOD-4023 in Growth Hormone Deficient
Adults. See abstract for more information.

ENDO 2013 abstracts are available online at:

ENDO 2013, the 95th Annual Meeting & Expo of the Endocrine Society, is being
held June 15-18, 2013, in San Francisco. For more information, visit:

PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying
unique technologies, including patented CTP technology and its long-acting
reversible-pegylation technology, primarily to develop longer-acting
proprietary versions of already approved therapeutic proteins that currently
generate billions of dollars in annual global sales. The CTP technology is
applicable to virtually all proteins. PROLOR is developing a long-acting
version of human growth hormone, which is in a Phase IIl clinical trial. It
also is developing long-acting versions of factor VIIa and factor IX for
hemophilia and a GLP-1/Glucagon dual receptor agonist peptide for diabetes and
obesity, all of which are in preclinical development. For more information,

Safe Harbor Statement: This press release contains forward-looking
statements, which may be identified by words such as "expects," "plans,"
"projects," "will," "may," "anticipates," "believes," "should," "would",
"intends," "estimates," "suggests," "has the potential to" and other words of
similar meaning, including statements regarding the results of current
clinical studies and preclinical experiments and the effectiveness of PROLOR's
long-acting protein programs, which are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. Investors
are cautioned that forward-looking statements involve risks and uncertainties
that may affect PROLOR's business and prospects, including the risks that
PROLOR may not succeed in generating any revenues or developing any commercial
products, including any long-acting versions of human growth hormone,
erythropoietin, interferon beta, GLP-1 and other products; that the
long-acting products in development may fail, may not achieve the expected
results or effectiveness and/or may not generate data that would support the
approval or marketing of these products for the indications being studied or
for other indications; that ongoing studies may not continue to show
substantial or any activity; that the actual dollar amount of any grants from
Israel's Office of the Chief Scientist is uncertain and is subject to policy
changes of the Israeli government, and that such grants may be insufficient to
assist with product development; and other risks and uncertainties that may
cause results to differ materially from those set forth in the forward-looking
statements. The results of clinical trials in humans may produce results that
differ significantly from the results of clinical and other trials in animals.
The results of early-stage trials may differ significantly from the results of
more developed, later-stage trials. The development of any products using the
CTP platform technology could also be affected by a number of other factors,
including unexpected safety, efficacy or manufacturing issues, additional time
requirements for data analyses and decision making, the impact of
pharmaceutical industry regulation, the impact of competitive products and
pricing and the impact of patents and other proprietary rights held by
competitors and other third parties. In addition to the risk factors
described above, investors should consider the economic, competitive,
governmental, technological and other factors discussed in PROLOR's filings
with the Securities and Exchange Commission. The forward-looking statements
contained in this press release speak only as of the date the statements were
made, and we do not undertake any obligation to update forward-looking
statements, except as required under applicable law.

Shai Novik, President          Barbara Lindheim
PROLOR Biotech, Inc.            BLL Partners, LLC
Tel: +1 866 644-7811              +1 212 584-2276


Press spacebar to pause and continue. Press esc to stop.